Dermiraincwas A Biopharmaceutical Company Based In Menlo Parkcaliforniafocused On Medical Dermatologyfounded In August 2010It Specialized In Therapies For Chronic Skin Conditionsincluding Hyperhidrosis And Atopic Dermatitisthecompany Operated As A Clinical Stageentity Until Its Acquisition By Eli Lilly In 2020 For $1 1 Billion Dermira Developed Innovativetreatments Such As Qbrexzaa Can Fda Approved Glycopyrronium Cloth For Treating Primary Axillary Hyperhidrosisand Lebrikizumaba Monoclonal Antibody For Moderateto Severeatopic Dermatitisthecompany Emphasized Patient Centric Outcomes And Conducted Latestageclinical Trials To Improvethequality Of Lifefor Individuals With Chronic Skin Conditionsfollowing Theacquisitiondermira S Assets And Pipelinewereintegrated Into Eli Lilly S Immunology Portfolio
